BioSpace News Archive

Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced that both its COVID-19 & Flu and COVID-19 molecular tests have received CE Mark for professional use, clearing both tests for sale and distribution throughout the European Union.

Comera Life Sciences, Inc. today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas.

Equillium, Inc. today announced that three posters were presented over the weekend at IMMUNOLOGY2022, the annual meeting of The American Association of Immunologists.

MannKind Corporation announced that it will be participating at upcoming conferences.

RadNet, Inc. reported financial results for its first quarter of 2022.

DaVita Inc. announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 11 a.m. EDT.

Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close.

Roger Dansey, M.D., Chief Medical Officer, Appointed Interim CEO The Board of Directors of Seagen Inc. announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence.

BIOLASE, Inc., the global leader in dental lasers, announced that Kenneth P. Yale, D.D.S., J.D. was newly elected to its Board of Directors, effective April 28, 2022.

Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.